期刊文献+

2015—2019年西安市第一医院β-内酰胺酶抑制剂复方制剂临床应用合理性分析 被引量:6

Evaluation of the rationality of clinical application ofβ-lactamase inhibitors compound in the First Hospital of Xi’an during 2015—2019 period
原文传递
导出
摘要 目的对西安市第一医院β-内酰胺类抗生素/β-内酰胺酶抑制剂复方制剂(简称β-内酰胺酶抑制剂复方制剂)的临床应用情况、用药趋势及合理性进行分析,为其规范化管理和临床合理用药提供参考。方法对2015—2019年西安市第一医院β-内酰胺酶抑制剂复方制剂的销售金额、用药频度(DDDs)、日均费用(DDC)、药品排序比(B/A)和科室分布等进行统计和分析,并抽取β-内酰胺酶抑制剂复方制剂住院病例500份,对其合理性进行评价。结果β-内酰胺酶抑制剂复方制剂销售金额和DDDs总体呈增长趋势,其中注射用美洛西林钠舒巴坦钠和注射用头孢哌酮钠舒巴坦钠位居前2位。DDC从2017年起有不同程度的下降,各品种间DDC差异较大。注射用美洛西林钠舒巴坦钠和注射用头孢哌酮钠舒巴坦钠B/A为1.00,同步性较好;注射用哌拉西林钠舒巴坦钠和注射用哌拉西林钠他唑巴坦钠B/A小于1.00,使用成本较高;注射用阿莫西林钠克拉维酸钾和阿莫西林克拉维酸钾分散片B/A大于1.00,使用成本较低。β-内酰胺酶抑制剂复方制剂科室分布于呼吸内科、泌尿外科、肾脏内分泌科、神经内科、神经外科、重症医学科、心血管内科、干部病房、康复医学科、儿科等,临床应用较广泛。抽取的500份应用β-内酰胺酶抑制剂复合制剂住院病例,有53例存在用药不合理的情况,其中适应症不适宜45例(9%),用药疗程不适宜4例(0.8%),用法用量不适宜3例(0.6%),联合用药不适宜1例(0.2%)。结论西安市第一医院β-内酰胺酶抑制剂复方制剂临床应用基本合理,但仍存在选择抗菌药物价格高和起点高的问题,今后应进一步加强对β-内酰胺酶抑制剂复方制剂的管理。 Objective To analyze the clinical application and trend ofβ-lactamase inhibitors compound in the hospital,and to provide reference for standardized management and rational clinical use of drug.Methods The data of utilization ofβ-lactamase inhibitors compound in the First Hospital of Xi’an from 2015 to 2019 were collected and analyzed statistically,and consumption sums,frequency of drug use(DDDs),defined daily cost(DDC),drug sequence ratio(B/A)and department distribution were calculated and analyzed.A retrospective analysis was made of 500 medical records of the patients usingβ-lactamase inhibitors compound,and the medication rationality ofβ-lactamase inhibitors compound was evaluated.Results The consumption sums and DDDs ofβ-lactamase inhibitor compound showed an overall growth trend,among which meloxicillin sodium sulbactam sodium for injection and cefoperazone sodium sulbactam sodium for injection were the top two.Since 2017,DDC has decreased to different degrees,and there was a big difference in DDC among varieties.B/A values of meroxicillin sodium sulbactam sodium for injection and cefoperazone sodium sulbactam sodium for injection were 1,indicating good synchronization.B/A values of piperacillin sodium sulbactam sodium for injection and piperacillin sodium tazobactam sodium for injection were less than 1,the use cost was higher;B/A values of amoxicillin sodium potassium clavulanate for injection and amoxicillin potassium clavulanate dispersible tablets were more than 1.Theβ-lactamase inhibitor compound was widely used in respiratory medicine,urology,kidney endocrinology,neurology,neurosurgery,intensive medicine,cardiovascular medicine,cadre ward,rehabilitation medicine,pediatrics,etc.There were 53 cases of irrational use records,in which,improper indications(9%),appropriate course of treatmen(0.8%),irrational dosage(0.6%)and improper drugCombination(0.2%)were the major problems.Conclusion The clinical application ofβ-lactamase inhibitor compounds is basically reasonable in the hospital,but there are still problems of high price and high starting point for the selection of antibiotics,so the management ofβ-lactamase inhibitor compounds should be further strengthened in the future.
作者 王丹 王颖丽 段石顽 WANG Dan;WANG Ying-Li;DUAN Shi-wan(Department of Pharmacy,Xi’an No.1 Hospital,Xi’an 710002,China)
出处 《现代药物与临床》 CAS 2020年第12期2467-2472,共6页 Drugs & Clinic
关键词 β-内酰胺酶抑制剂复方制剂 临床应用 合理性 注射用美洛西林钠舒巴坦钠 注射用头孢哌酮钠舒巴坦钠 β-lactamase inhibitor compounds clinical application rationality meloxicillin sodium sulbactam sodium for injection cefoperazone sodium sulbactam sodium for injection
  • 相关文献

参考文献3

二级参考文献38

  • 1周颖杰,李光辉.成人及儿童复杂性腹腔内感染的诊断与处理:美国外科感染学会及美国感染病学会指南[J].中国感染与化疗杂志,2010,10(4):241-247. 被引量:240
  • 2梁若玲,梁汝坚,贾道全.奥美拉唑肠溶片为主三联根除幽门螺杆菌方案研究[J].实用医学杂志,2004,20(6):703-704. 被引量:6
  • 3Mor A,Thomsen RW,Ulrichsen SP,et al.Chronic heart failure and risk of hospitalization with pneumonia:a population-based study[J].Eur J Intern Med,2013Jun;24(4):49-53.
  • 4Harjai K J,Samal A,Shah M,et al.The relationship between left ventricular shape and QT interval dispersion[J].Echocardiography,2012,19 (8):641.
  • 5Haugaa KH,Bos JM,Tarrell RF,et al.Institution-wide QT alert system identifies patients with a high risk of mortality[J].Mayo Clin Proc,2013,88(4):15-25.
  • 6Kennelly C,Esaian D.Drug-induced cardiovascular adverse events in the intensive care unit[J].Crit Care Nurs Q,2013,36(4):23-34.
  • 7Green CL,Whellan DJ,Lambe L,et al.Electrocardiographic Safety of Cangrelor,a New Intravenous Anti-platelet Agent:A Randomized,Double-Blind,Placebo-and Moxifloxacin-Controlled Thorough QT Study[J].J Cardiovasc Pharmacol,2013,8 (4):69-73.
  • 8Hibino S,Ueda N,Horiba M,et al.Detection of QT Prolongation Through Approximation of the T Wave on Gaussian Mixture Modeling[J].Diagn Microbiol Infect Dis,2013,8(26):319-322.
  • 9Márquez MF.Long QT syndrome:a brief review of the electrocardiographical diagnosis including Viskin's test[J].Arch Cardiol Mex,2012,82(3):243-247.
  • 10Mortara DW.Automated QT measurement and application to detection of moxifloxacin-induced changes[J].Ann Noninvasive Electrocardiol,2009,47 (7):625-630.

共引文献111

同被引文献84

引证文献6

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部